TREE NEWS reports: Amundi Group Chief Investment Officer Vincent Mortier said investors have been “overly fixated” on core AI companies, but that focus will shift by 2027. Europe’s largest asset manager now favors sectors using AI to drive productivity and business transformation, including pharmaceuticals, biotech and some industrial firms. Mortier said the core AI segment is in the early stages of repricing, calling the adjustment “normal” after its extraordinary rally.
Amundi CIO: AI focus to shift by 2027 as core AI stocks reprice
The significance here is less the 2027 timeline than the source: Europe's largest asset manager publicly calling the core AI trade over-owned and already repricing. That framing matters for anyone whose RWA or tokenization thesis leans on the same mega-cap AI names for liquidity and sentiment. The rotation Mortier describes—toward pharma, biotech and industrial adopters—implies a market that rewards AI users over AI builders, a distinction that has not yet been tested in this cycle. Whether that repricing stays orderly, as he suggests, is the open question worth watching.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.